Atara Biotherapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Atara Biotherapeutics generated cash of -$192,977,000, which is more than the previous year. Cash used in financing activities reached the amount of $2,009,999 last year. Net change in cash is therefore -$67,101,000.
Cash Flow
| 2014 | -16.62M | -83.36M | 70.27M |
|---|---|---|---|
| 2015 | -37.15M | -220.12M | 259.22M |
| 2016 | -60.02M | 83.74M | 506K |
| 2017 | -87.50M | 98.70M | 20.04M |
| 2018 | -179.77M | -196.28M | 357.53M |
| 2019 | -235.62M | 60.45M | 188.78M |
| 2020 | -180.75M | -120.72M | 427.57M |
| 2021 | -220.52M | 22.25M | 103.94M |
| 2022 | -270.43M | 202.95M | 53.08M |
| 2023 | -192.97M | 123.86M | 2.00M |
ATRA Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 93.08M | 107.47M | 201.79M | 75.71M | 62.09M | 80.61M | 47.96M | 23.74M | 21.89M | 51.61M |
Operating activities | ||||||||||
Net income | -276.12M | -228.30M | -340.14M | -306.62M | -290.97M | -230.69M | -119.49M | -79.04M | -57.22M | -28.00M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 4.82M | 5.65M | 9.34M | 8.33M | 7.07M | 3.73M | 956K | 383K | 48K | 6K |
Stock-based compensation expense | 45.38M | 53.83M | 53.86M | 51.35M | 51.69M | 0 | 23.1M | 16.78M | 10.25M | 10.10M |
| Deferred income tax benefit | 45.38M | 53.83M | 53.86M | 51.35M | 51.69M | 0 | 23.1M | 16.78M | 10.25M | 10.10M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 6.11M | -39.23M | 264K | -1.25M | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | -8.11M | -1.58M | 3.34M | -1.25M | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -3.13M | -9.21M | 9.06M | -815K | 4.21M | -1.95M | 2.16M | 981K | 1.00M | -164K |
Cash generated by operating activities | -192.97M | -270.43M | -220.52M | -180.75M | -235.62M | -179.77M | -87.50M | -60.02M | -37.15M | -16.62M |
Investing activities | ||||||||||
Purchases Of Investments | -83.64M | -180.58M | -301.12M | -425.86M | -270.23M | -466.48M | -176.45M | -304.92M | -379.77M | -95.52M |
Investments In Property Plant And Equipment | -1.22M | -4.19M | -10.58M | -4.51M | -5.73M | -35.92M | -20.23M | -3.02M | -290K | -46K |
Acquisitions Net | 0 | 94.76M | -32.83M | 116.21M | 161K | 0 | 0 | -83.74M | 0 | 0 |
Cash generated by investing activities | 123.86M | 202.95M | 22.25M | -120.72M | 60.45M | -196.28M | 98.70M | 83.74M | -220.12M | -83.36M |
Financing activities | ||||||||||
Common Stock Issued | 2.13M | 21.89M | 105.45M | 422.96M | 188.61M | 0 | 19.15M | 0 | 263.43M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | -1.24M | -1.52M | 0 | -7.50M | 0 | -94K | 0 | 0 |
Repayments of term debt | -947K | -518K | -254K | -389K | -486K | -528K | 0 | 0 | 0 | 0 |
Cash used in financing activities | 2.00M | 53.08M | 103.94M | 427.57M | 188.78M | 357.53M | 20.04M | 506K | 259.22M | 70.27M |
Net Change In Cash | -67.10M | -14.39M | -94.32M | 126.08M | 13.61M | -18.52M | 31.25M | 24.22M | 1.84M | -29.71M |
Cash at end of period | 25.98M | 93.08M | 107.47M | 201.79M | 75.71M | 62.09M | 79.22M | 47.96M | 23.74M | 21.89M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |